FR2222104A1 - - Google Patents

Info

Publication number
FR2222104A1
FR2222104A1 FR7401391A FR7401391A FR2222104A1 FR 2222104 A1 FR2222104 A1 FR 2222104A1 FR 7401391 A FR7401391 A FR 7401391A FR 7401391 A FR7401391 A FR 7401391A FR 2222104 A1 FR2222104 A1 FR 2222104A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7401391A
Other languages
French (fr)
Other versions
FR2222104B1 (enExample
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Laboratories Inc filed Critical Baxter Laboratories Inc
Publication of FR2222104A1 publication Critical patent/FR2222104A1/fr
Application granted granted Critical
Publication of FR2222104B1 publication Critical patent/FR2222104B1/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/1027—Making of balloon catheters
    • A61M25/1034—Joining of shaft and balloon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/1027—Making of balloon catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/1027—Making of balloon catheters
    • A61M25/1036—Making parts for balloon catheter systems, e.g. shafts or distal ends
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T156/00—Adhesive bonding and miscellaneous chemical manufacture
    • Y10T156/11—Methods of delaminating, per se; i.e., separating at bonding face
    • Y10T156/1142—Changing dimension during delaminating [e.g., crushing, expanding, warping, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
FR7401391A 1973-03-21 1974-01-16 Expired FR2222104B1 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US00343606A US3832253A (en) 1973-03-21 1973-03-21 Method of making an inflatable balloon catheter

Publications (2)

Publication Number Publication Date
FR2222104A1 true FR2222104A1 (enExample) 1974-10-18
FR2222104B1 FR2222104B1 (enExample) 1978-11-10

Family

ID=23346788

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7401391A Expired FR2222104B1 (enExample) 1973-03-21 1974-01-16

Country Status (16)

Country Link
US (1) US3832253A (enExample)
JP (1) JPS5632944B2 (enExample)
AR (1) AR198035A1 (enExample)
BE (1) BE807897A (enExample)
BR (1) BR7402164D0 (enExample)
CA (1) CA1007431A (enExample)
DE (1) DE2401549A1 (enExample)
ES (1) ES424452A1 (enExample)
FR (1) FR2222104B1 (enExample)
GB (1) GB1436679A (enExample)
IE (1) IE39749B1 (enExample)
IL (1) IL43868A (enExample)
IT (1) IT1008888B (enExample)
NL (1) NL7403100A (enExample)
SE (1) SE398048B (enExample)
ZA (1) ZA738877B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2399852A1 (fr) * 1977-08-10 1979-03-09 Kendall & Co Manchette gonflable pour catheter et catheter en comportant application
FR2434629A1 (fr) * 1978-08-30 1980-03-28 Ruesch Gmbh & Co Kg Willy Procede de fabrication d'un instrument medical, notamment d'un tube d'un catheter
FR2513566A1 (fr) * 1981-09-29 1983-04-01 Matburn Holdings Ltd Procede pour fixer ensemble les matieres plastiques et le caoutchouc

Families Citing this family (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210478A (en) * 1973-05-08 1980-07-01 International Paper Company Method of making a catheter
US3959429A (en) * 1975-02-03 1976-05-25 International Paper Company Method of making a retention catheter and molding a tip thereon
US3985601A (en) * 1975-05-05 1976-10-12 Quantum, Inc. Method for producing a balloon type catheter having a smooth continuous outer surface
US4361152A (en) * 1975-05-27 1982-11-30 The Kendall Company Catheter
US4055187A (en) * 1976-08-05 1977-10-25 The Kendall Company Catheter with improved balloon assembly
US4188954A (en) * 1976-08-05 1980-02-19 The Kendall Company Catheter with improved balloon assembly
US4082114A (en) * 1977-01-28 1978-04-04 The Trane Company Valve assembly for use in an air distribution system
FR2386406A1 (fr) * 1977-04-08 1978-11-03 Technological Supply Procede pour la fabrication d'un catheter a ballonnet
US4143651A (en) * 1977-11-03 1979-03-13 The Kendall Company Catheter
US4222384A (en) * 1977-11-09 1980-09-16 Biomedical Engineering Associates, Inc. Catheter
JPS552348U (enExample) * 1978-06-21 1980-01-09
US4284459A (en) * 1978-07-03 1981-08-18 The Kendall Company Method for making a molded catheter
US4251305A (en) * 1978-11-01 1981-02-17 Baxter Travenol Laboratories, Inc. Method of radiant heat sealing of a balloon onto a catheter employing tinted shrink tubing
JPS56152655A (en) * 1980-04-28 1981-11-26 Terumo Corp Balloon catheter with backward flow preventing valve
US4445890A (en) * 1980-05-05 1984-05-01 The Kendall Company Catheter
US4447228A (en) * 1980-05-05 1984-05-08 The Kendall Company Catheter
US4445891A (en) * 1980-05-05 1984-05-01 The Kendall Company Catheter
FR2521014B1 (fr) * 1982-02-05 1988-06-03 Matburn Holdings Ltd Instrument chirurgical tubulaire, notamment catheter de thrombectomie
DE3438131C2 (de) * 1984-10-18 1986-08-21 Werner Dr.med. 4330 Mülheim Schubert Vorrichtung zur Beseitigung von Konkrementen
US4787892A (en) * 1984-12-18 1988-11-29 The Kendall Company Nephrostomy catheter with formed tip
US4636272A (en) * 1985-02-19 1987-01-13 Cordis Corporation Process for thermally bonding plastic tubes
US4782834A (en) * 1987-01-06 1988-11-08 Advanced Cardiovascular Systems, Inc. Dual lumen dilatation catheter and method of manufacturing the same
US4861337A (en) * 1988-03-02 1989-08-29 Sherwood Medical Company Collapsible urethral catheter
US5095915A (en) * 1990-03-19 1992-03-17 Target Therapeutics Guidewire with flexible distal tip
JP2502174B2 (ja) * 1990-08-07 1996-05-29 富士システムズ株式会社 バル―ンカテ―テルの製造方法
US5257451A (en) * 1991-11-08 1993-11-02 Ep Technologies, Inc. Method of making durable sleeve for enclosing a bendable electrode tip assembly
US5460608A (en) * 1994-01-25 1995-10-24 Scimed Life Systems, Inc. Kink free catheter
SE9404486D0 (sv) * 1994-12-22 1994-12-22 Astra Ab Catheter
US5527281A (en) * 1995-07-27 1996-06-18 Haas; Joseph A. Substitute tip for urethral catheter
SE9600276D0 (sv) 1996-01-25 1996-01-25 Astra Ab A wetting device for wetting a hydrophilic catheter and a urine collection bag incorporating said device
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6040147A (en) 1997-04-02 2000-03-21 The Brigham And Women's Hospital, Inc. Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
EP1967203A1 (en) 1998-07-15 2008-09-10 The Brigham and Women's Hospital Polysaccharide vaccine for staphylococcal infections
US6368301B1 (en) 1999-12-21 2002-04-09 Advanced Cardiovascular Systems, Inc. Catheter having a soft distal tip
EP1266013B1 (en) 2000-03-08 2014-10-15 Massachusetts Institute Of Technology Heparinase iii and uses thereof
EP1328261A2 (en) * 2000-04-12 2003-07-23 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
KR100434720B1 (ko) * 2001-01-03 2004-06-07 이근호 발룬 카테테르의 제조방법
US6692461B2 (en) 2001-08-07 2004-02-17 Advanced Cardiovascular Systems, Inc. Catheter tip
US6918920B1 (en) * 2001-11-01 2005-07-19 Advanced Cardiovascular Systems, Inc. Catheter having an improved distal tip
AU2003225724A1 (en) 2002-03-11 2003-09-29 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
WO2003078448A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
US7344505B2 (en) * 2002-10-15 2008-03-18 Transoma Medical, Inc. Barriers and methods for pressure measurement catheters
WO2004078928A2 (en) 2003-02-28 2004-09-16 The Johns Hopkins University T cell regulation
WO2005019819A1 (en) 2003-08-20 2005-03-03 Biosite, Inc. Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
EP1651207A4 (en) 2003-06-12 2008-10-01 Univ Colorado SYSTEMS AND METHODS FOR THE TREATMENT OF HUMAN INFLAMMATORY AND PROLIFERATIVE DISEASES AND INJURIES USING INHIBITORS OF FATTY ACID METABOLISM AND / OR GLYCOLYTIC INHIBITORS
US7655000B2 (en) 2003-09-26 2010-02-02 Tyco Healthcare Group Lp Urology catheter
US7972350B2 (en) * 2004-01-29 2011-07-05 Boston Scientific Scimed, Inc. Catheter tip
JP5230865B2 (ja) * 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ結合性化合物
CN101106997A (zh) 2004-08-17 2008-01-16 约翰·霍普金斯大学 Pde5抑制剂组合物及治疗心脏病征候的方法
EP2338994B1 (en) * 2004-09-02 2014-03-19 Yale University Regulation of oncogenes by microRNAs
US20080138847A1 (en) * 2004-09-23 2008-06-12 Yigong Shi Bcl-2 family member and BH-3 only proteins for use in development of peptidomimetics
EP1809759B1 (en) 2004-10-06 2013-09-11 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
WO2006052940A2 (en) * 2004-11-05 2006-05-18 Asthmatx, Inc. Medical device with procedure improvement features
EP1843734A4 (en) 2005-02-03 2008-09-10 Signum Biosciences Inc COMPOSITIONS AND METHOD FOR INTENSIFYING COGNITIVE FUNCTIONS
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP1858542A4 (en) * 2005-02-24 2009-08-19 Joslin Diabetes Center Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VASPEREPERMABILITY
US7517906B2 (en) * 2005-02-25 2009-04-14 Tetralogic Pharmaceuticals Corporation Dimeric IAP inhibitors
WO2007002528A1 (en) * 2005-06-23 2007-01-04 Yale University Anti-aging micrornas
JP2009502790A (ja) 2005-07-19 2009-01-29 ザ ユニバーシティー オブ テネシー リサーチ ファウンデーション Ｃｆｔｒのｌｐａ２受容体アゴニスト阻害因子
CN101267779A (zh) 2005-07-27 2008-09-17 福罗里达大学研究基金会有限公司 使用热休克治疗眼睛疾病
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
CA2617642A1 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US20080021198A1 (en) * 2005-10-12 2008-01-24 Yigong Shi Modulators of protein phosphatase 2A and PP2A methyl esterase
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
CA2631731A1 (en) * 2005-12-01 2007-06-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting apoptosis
CL2007002166A1 (es) * 2006-07-24 2008-01-25 Tetralogic Pharm Corp Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
BRPI0715195A2 (pt) 2006-07-24 2013-06-11 Tetralogic Pharm Corp composto, mÉtodos para induzir e para estimular a apoptose em uma cÉlula, para intensificar a apoptose de cÉlulas patogÊnicas in vivo em um indivÍduo, e para tratar uma doenÇa, e, composiÇço farmacÊutica
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20080153773A1 (en) * 2006-08-08 2008-06-26 Yigong Shi Modulators of phosphotyrosyl phosphatase activator
US20100092480A1 (en) * 2006-10-13 2010-04-15 The Trustees Of The University Of Princeton Modulators of protein phosphatase 2a
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
JP2010515434A (ja) 2007-01-05 2010-05-13 マサチューセッツ インスティテュート オブ テクノロジー Ｆｌａｖｏｂａｃｔｅｒｉｕｍｈｅｐａｒｉｎｕｍ由来のスルファターゼを使用する組成物および方法
EP2099911A2 (en) * 2007-01-11 2009-09-16 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
WO2008109773A2 (en) * 2007-03-06 2008-09-12 Cornell Research Foundation, Inc. Chronic obstructive pulmonary disease susceptibility and related compositions and methods
WO2008116216A1 (en) * 2007-03-22 2008-09-25 Medical College Of Georgia Research Institute, Inc. Compositions and methods for inhibiting cancer metastasis
WO2008122039A2 (en) * 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
WO2008153987A2 (en) 2007-06-08 2008-12-18 The Government Of The United States Of America As Represented By The Secretary Of Department Of Health And Human Services Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells
US20090274682A1 (en) * 2008-02-05 2009-11-05 The Trustees Of Princeton University Demethylation and inactivation of protein phosphatase 2a
WO2009108745A1 (en) * 2008-02-26 2009-09-03 The Trustees Of Princeton University Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation
CN102076853A (zh) * 2008-05-07 2011-05-25 阿布拉西斯生物科学有限责任公司 通过miRNA增强药物疗法
US20100146875A1 (en) * 2008-05-30 2010-06-17 John Redding Support post structure
US9273136B2 (en) * 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
JP2012503004A (ja) 2008-09-17 2012-02-02 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
US8729053B2 (en) * 2008-09-22 2014-05-20 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Nuclear factor kappa B pathway inhibitor composition and use of same
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
WO2010124188A1 (en) 2009-04-23 2010-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
ES2675236T3 (es) 2009-04-30 2018-07-09 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Schweinfurthinas y usos de las mismas
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
IN2012DN00352A (enExample) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
US20120269765A1 (en) 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
EP2287304A1 (en) 2009-08-17 2011-02-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel treatment of patients after stent implantation or balloon dilatation and novel drug eluting stents
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
EP2526122B1 (en) * 2010-01-19 2020-06-10 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
US20110262406A1 (en) 2010-04-21 2011-10-27 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
US20110293585A1 (en) 2010-04-21 2011-12-01 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
WO2012012627A1 (en) 2010-07-22 2012-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of preventing or treating viral infection
US9758586B2 (en) 2010-12-01 2017-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ROR1 antibodies
MX2013008944A (es) 2011-02-03 2014-01-08 Mirna Therapeutics Inc Mimeticos sinteticos de mir-124.
WO2012106591A1 (en) 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
WO2012125623A2 (en) 2011-03-14 2012-09-20 Ludwig Institute For Cancer Research Ltd. Cleavage inhibitors of transforming growth factor beta type i receptor and uses thereof in cancer therapy
PT3459560T (pt) 2011-04-08 2021-05-24 Us Health Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização dos mesmos para o tratamento de cancro
CN105148285B (zh) 2011-04-21 2019-02-12 塔夫茨大学信托人 用于活性试剂稳定化的方法和组合物
EA026121B1 (ru) 2011-06-14 2017-03-31 Бикам Фармасьютикалз, Инк. Опсин-связывающие лиганды, композиции и способы их использования
US8759313B2 (en) 2011-08-03 2014-06-24 The Charlotte-Mecklenburg Hospital Authority Treatment of fibrosis using microRNA 19b
US9593160B2 (en) 2011-07-18 2017-03-14 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
EP2768307B1 (en) 2011-10-19 2020-03-18 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
RU2644243C2 (ru) 2011-10-20 2018-02-08 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы к cd22
US9353063B2 (en) 2011-11-30 2016-05-31 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
AU2012346537A1 (en) 2011-12-01 2014-07-17 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US9359447B2 (en) 2012-03-23 2016-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
AU2013252785B2 (en) 2012-04-27 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of CpG oligonucleotides co-formulated with an antibiotic to accelarate wound healing
EP3505537A1 (en) 2012-05-07 2019-07-03 Trustees of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
JP2015526471A (ja) 2012-08-21 2015-09-10 ジェネシス リサーチ インスティチュート アントラサイクリン誘発性心毒性を治療または予防するための組成物および方法
JP6338252B2 (ja) 2012-10-24 2018-06-06 アメリカ合衆国 Ｍ９７１キメラ抗原受容体
EP2931272A1 (en) 2012-12-12 2015-10-21 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System Methods of treating hepatic fibrosis and associated diseases by regulating rev-erb activity
WO2014093726A1 (en) 2012-12-12 2014-06-19 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System Methods of treating portal hypertension
CN105358708B (zh) 2013-03-14 2024-07-16 儿童医学中心公司 Cd36鉴定癌症对象以用于治疗的用途
KR102774944B1 (ko) 2013-03-15 2025-02-27 트러스티즈 오브 터프츠 칼리지 저분자량 실크 조성물 및 안정화 실크 조성물
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
JP2016522165A (ja) 2013-04-04 2016-07-28 イエオ−イスティトゥート・エウロペオ・ディ・オンコロジア・エッセ・エッレ・エッレ 胸腺間質性リンパ球新生因子フラグメント及びその使用
US10274503B2 (en) 2013-05-08 2019-04-30 Vegenics Pty Limited Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
ES2828642T3 (es) 2013-06-25 2021-05-27 Walter & Eliza Hall Inst Medical Res Miméticos Smac para el tratamiento de una infección intracelular persistente de VHB
WO2015006543A1 (en) 2013-07-10 2015-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for predicting and detecting tumor metastasis in kidney cancer
US9925241B2 (en) 2013-10-21 2018-03-27 Salk Institute For Biological Studies Mutated fibroblast growth factor (FGF) 1 and methods of use
RU2701346C1 (ru) 2013-12-06 2019-09-25 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения
EP3083658B1 (en) 2013-12-18 2019-05-08 President and Fellows of Harvard College Crp capture/detection of gram positive bacteria
WO2015148801A1 (en) 2014-03-26 2015-10-01 Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof
US10272019B2 (en) 2014-05-09 2019-04-30 Yale University Topical formulation of hyperbranched polyglycerol-coated particles thereof
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
EP3193933B1 (en) 2014-09-17 2021-04-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-cd276 antibodies (b7h3)
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
BR112017026209A2 (pt) 2015-06-05 2018-11-27 Ibio, Inc. fragmentos e variantes de endostatinas para uso no tratamento de fibrose
EP3831844B1 (en) 2015-06-26 2024-03-13 Prindex S.r.l. Diagnosis and therapy of multiple sclerosis
WO2017004142A1 (en) 2015-06-29 2017-01-05 Children's Medical Center Corporation Treatment for myopathy
CN108289928B (zh) 2015-08-06 2024-09-17 哈佛大学校长及研究员协会 改进的微生物-结合分子和其用途
UA125718C2 (uk) 2016-01-20 2022-05-25 Зе Скріппс Ресеарч Інстітьют Композиції антитіл до ror1 і пов'язані з ними способи
AU2017209313A1 (en) 2016-01-20 2018-08-09 The Scripps Research Institute ROR2 antibody compositions and related methods
US11136597B2 (en) 2016-02-16 2021-10-05 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
WO2017143061A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
CA3020863A1 (en) 2016-04-19 2017-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
WO2017198631A1 (en) 2016-05-16 2017-11-23 Istituto Nazionale Di Genetica Molecolare - Ingm Markers selectively deregulated in tumor-infiltrating regulatory t cells
EP4413999A3 (en) 2016-05-27 2024-08-28 The United States of America, as represented by the Secretary, Department of Health and Human Services Flt3-specific chimeric antigen receptors and methods using same
WO2017207623A1 (en) 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
WO2018005799A1 (en) 2016-06-29 2018-01-04 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
WO2018005759A1 (en) 2016-07-01 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
WO2018200722A1 (en) 2017-04-25 2018-11-01 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins
CA3099487A1 (en) 2017-07-20 2019-01-24 Nbe-Therapeutics Ag Human antibodies binding to ror2
WO2019030240A1 (en) 2017-08-07 2019-02-14 Nbe-Therapeutics Ag ANTIBODIES BINDING TO A LINEAR HUMAN CS1 EPITOPE
WO2019154884A1 (en) 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
EP3790563A4 (en) 2018-05-11 2022-03-23 Forte Subsidiary, Inc. Compositions for the treatment of skin conditions
JP2022508619A (ja) 2018-10-04 2022-01-19 ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー ニューロメジンペプチドを使用して２型サイトカイン媒介性炎症を低減させる方法
US11266617B2 (en) 2018-10-16 2022-03-08 Massachusetts Institute Of Technology Beta-hydroxybutyrate encapsulated PLGA nanoparticle compositions
US20210340562A1 (en) 2018-10-19 2021-11-04 Board Of Regents, The University Of Texas System Engineered long interspersed element (line) transposons and methods of use
EP3677693A1 (en) 2019-01-03 2020-07-08 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Transpochimeric gene trancripts (tcgts) as cancer biomarkers
EP3911677A1 (en) 2019-01-18 2021-11-24 Janssen Biotech, Inc. Gprc5d chimeric antigen receptors and cells expressing the same
AU2020215177A1 (en) 2019-01-30 2021-08-12 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
WO2020186187A1 (en) 2019-03-13 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
JP2022526194A (ja) 2019-04-10 2022-05-23 エレベートバイオ テクノロジーズ，インコーポレイテッド Ｆｌｔ３特異的キメラ抗原受容体およびその使用方法
CA3139032A1 (en) 2019-05-22 2020-11-26 Robert Alexander WESSELHOEFT Circular rna compositions and methods
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
US20220243211A1 (en) 2019-06-21 2022-08-04 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
WO2020257779A1 (en) 2019-06-21 2020-12-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
BR112022001331A2 (pt) 2019-07-26 2022-06-14 Janssen Biotech Inc Receptor quimérico de antígeno (car) anti-hk2
UY38803A (es) 2019-07-26 2021-01-29 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y usos de las mismas
US12496357B2 (en) 2019-07-31 2025-12-16 Yale University Compositions and methods for treating sickle cell disease
CN112390894A (zh) 2019-08-12 2021-02-23 广东东阳光药业有限公司 嵌合抗原受体及其应用
CA3151344A1 (en) 2019-08-16 2021-02-25 Janssen Biotech, Inc. Therapeutic immune cells with improved function and methods for making the same
IL293046A (en) 2019-11-18 2022-07-01 Janssen Biotech Inc Anti-cd79 chimeric antigen receptors, car-t cells and uses thereof
IL271778A (en) 2019-12-31 2021-06-30 Ichilov Tech Ltd Methods for treating atopic dermatitis
EP3868396A1 (en) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitors and uses thereof
EP4110316A4 (en) 2020-02-26 2024-08-28 Case Western Reserve University Compositions and methods for treating misfolded protein ocular disorders
CA3171113A1 (en) 2020-03-13 2021-09-16 Patrick John DOONAN Materials and methods for binding siglec-3/cd33
US20230181672A1 (en) 2020-05-07 2023-06-15 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
WO2021236855A1 (en) 2020-05-19 2021-11-25 Orna Therapeutics, Inc. Circular rna compositions and methods
CN116322776A (zh) 2020-08-03 2023-06-23 詹森生物科技公司 用于病毒治疗剂中的多向生物转运的材料和方法
CN112295084B (zh) * 2020-09-25 2023-03-28 池州市琼琚信息技术服务有限公司 一种热收缩膜固定胶水形状的方法
US20240042053A1 (en) 2020-10-16 2024-02-08 University Of Georgia Research Foundation, Inc. Glycoconjugates
EP4059498A1 (en) 2021-03-16 2022-09-21 Centre Hospitalier Universitaire Vaudois (CHUV) Methods and compositions for treating conditions associated with hypermineralization
EP4314055A1 (en) 2021-03-24 2024-02-07 Janssen Biotech, Inc. Antibody targeting cd22 and cd79b
WO2022237974A1 (en) 2021-05-12 2022-11-17 Ecole Polytechnique Federale De Lausanne (Epfl) Krab-containing zinc finger protein and cancer
CN115404240A (zh) 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
WO2022261115A1 (en) 2021-06-07 2022-12-15 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
WO2022271955A1 (en) 2021-06-23 2022-12-29 Musc Foundation For Research Development Novel targeted shrna nanoparticles for cancer therapy
EP4392455A4 (en) 2021-08-25 2025-08-20 Ibio Inc ANTI-CD-25 ANTIBODIES
US20250019455A1 (en) 2021-09-24 2025-01-16 Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
CA3236235A1 (en) 2021-11-08 2023-05-11 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
WO2023231959A2 (en) 2022-05-30 2023-12-07 Shanghai Circode Biomed Co., Ltd Synthetic circular rna compositions and methods of use thereof
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
WO2024094526A1 (en) 2022-11-02 2024-05-10 Ecole Polytechnique Federale De Lausanne (Epfl) 6-diazo-5-oxo-l-norleucine prodrugs
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
TW202425959A (zh) 2022-11-08 2024-07-01 美商歐納醫療公司 遞送多核苷酸的脂質及奈米顆粒組合物
EP4634390A2 (en) 2022-12-15 2025-10-22 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
AU2024269222A1 (en) 2023-05-05 2025-10-09 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024263649A1 (en) 2023-06-19 2024-12-26 Yale University Methods and compositions for enrichment and sequencing of expansion-specific rna transcripts
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
WO2025021993A1 (en) 2023-07-27 2025-01-30 Omnilinx Therapeutics Ag Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
EP4537907A1 (en) 2023-10-10 2025-04-16 Enthera S.r.l. Cd248 inhibitors and uses thereof
WO2025117969A1 (en) 2023-12-01 2025-06-05 Orna Therapeutics, Inc. Process for manufacturing lipid nanoparticles
WO2025247961A1 (en) 2024-05-31 2025-12-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Lpa-lpar signaling as a therapeutic target or diagnostic tool for brain diseases
WO2025257173A1 (en) 2024-06-13 2025-12-18 Ideogen A.G. Combination therapy for treating cancer such as lymphoma
WO2025257176A1 (en) 2024-06-13 2025-12-18 Ideogen A.G. Combination therapy for treating cancer such as lymphoma
WO2025257171A1 (en) 2024-06-13 2025-12-18 Ideogen A.G. Combination therapy for treating cancer such as lymphoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEANT *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2399852A1 (fr) * 1977-08-10 1979-03-09 Kendall & Co Manchette gonflable pour catheter et catheter en comportant application
FR2434629A1 (fr) * 1978-08-30 1980-03-28 Ruesch Gmbh & Co Kg Willy Procede de fabrication d'un instrument medical, notamment d'un tube d'un catheter
FR2513566A1 (fr) * 1981-09-29 1983-04-01 Matburn Holdings Ltd Procede pour fixer ensemble les matieres plastiques et le caoutchouc

Also Published As

Publication number Publication date
AR198035A1 (es) 1974-05-24
IT1008888B (it) 1976-11-30
ZA738877B (en) 1974-10-30
GB1436679A (en) 1976-05-19
SE398048B (sv) 1977-12-05
US3832253A (en) 1974-08-27
FR2222104B1 (enExample) 1978-11-10
DE2401549A1 (de) 1974-10-03
NL7403100A (enExample) 1974-09-24
IL43868A0 (en) 1974-03-14
JPS5632944B2 (enExample) 1981-07-31
IL43868A (en) 1976-10-31
BR7402164D0 (pt) 1974-12-03
IE39749L (en) 1974-09-21
JPS508389A (enExample) 1975-01-28
CA1007431A (en) 1977-03-29
IE39749B1 (en) 1978-12-20
BE807897A (fr) 1974-03-15
ES424452A1 (es) 1976-06-16
AU6686274A (en) 1975-09-25

Similar Documents

Publication Publication Date Title
AR201758A1 (enExample)
AU476761B2 (enExample)
AU465372B2 (enExample)
JPS508389A (enExample)
AR201235Q (enExample)
AR201231Q (enExample)
AU474593B2 (enExample)
AU474511B2 (enExample)
AU474838B2 (enExample)
AU471343B2 (enExample)
AU465453B2 (enExample)
AU465434B2 (enExample)
AU450229B2 (enExample)
AU476714B2 (enExample)
AR201229Q (enExample)
AU466283B2 (enExample)
AR199451A1 (enExample)
AU476696B2 (enExample)
AU472848B2 (enExample)
AU477823B2 (enExample)
AR200885A1 (enExample)
AR195948A1 (enExample)
AR200256A1 (enExample)
AU477824B2 (enExample)
AR195311A1 (enExample)

Legal Events

Date Code Title Description
CD Change of name or company name
ST Notification of lapse